Dermasarra Lawsuit | 2025 Latest Updates

If you, a loved one, or anyone under your care developed a serious infection or health complication after using Dermasarra analgesic products, you may be eligible for legal compensation. At Schmidt & Clark, we specialize in representing individuals harmed by contaminated personal care items.

Our legal team stands ready to assist with evidence gathering, medical documentation, and pursuing the compensation you deserve. Contact Schmidt & Clark today for a free, no-obligation consultation.

What’s the Problem?

This case stems from a voluntary nationwide recall issued by DermaRite Industries involving Dermasarra external analgesic, alongside DermaKleen antiseptic lotion and KleenFoam antimicrobial foam, due to contamination with Burkholderia cepacia complex—a bacterium capable of causing life-threatening infections in vulnerable individuals.

Though no confirmed illnesses have been reported, the presence of such bacteria in topical skincare products poses elevated risks, especially for those with impaired immunity, open wounds, or chronic skin conditions.

Latest Dermasarra Lawsuit Updates

• Recall Announcement – August 8, 2025: DermaRite initiates a voluntary, nationwide recall of Dermasarra, DermaKleen, KleenFoam, and related products after internal testing detected contamination [1.].

Dermasarra Lawsuit Statistics & Scope

• Product Types: Dermasarra external analgesic, alongside DermaKleen and KleenFoam, across multiple lot codes.
• Distribution Reach: Recalled products were widely distributed nationwide via retail pharmacies, healthcare facilities, and online platforms.
• Reported Illnesses: As of now, there are no publicly confirmed cases of Dermasarra-related infections, though risk remains significant.
• Legal Posture: No class action lawsuits have been filed to date; legal counsel is beginning to evaluate consumer concerns.

Health Risk & Safety Overview

• Pathogen Details: Burkholderia cepacia can cause serious pulmonary issues, systemic infections, or sepsis when introduced via broken skin or compromised immune systems.
• Affected Users: Individuals with open wounds, chronic conditions (such as diabetes or COPD), or undergoing medical treatment are particularly at risk.
• Product Usage: Dermasarra is designed for topical pain relief; any contamination undermines its intended safety profile.

Potential Injuries & Impacts

Exposure to contaminated Dermasarra may result in:

• Localized infections: Redness, swelling, or abscess formation in areas where product was applied.
• Serious systemic infections: Bacteremia, pneumonia, or sepsis requiring hospitalization.
• Prolonged medical treatment: Involving IV antibiotics, extended care, or specialized wound management.

Do You Qualify for a Dermasarra Lawsuit?

• You used Dermasarra analgesic from recalled lots.
• You developed an infection or received medical care after using Dermasarra.
• A healthcare provider linked your condition to possible contamination.
• You have documentation: products, medical records, or purchase receipts.
• No case has yet been filed on your behalf, and you seek legal assessment.

Documentation You’ll Need

• Proof of use: receipts, product packaging, lot numbers or dates.
• Medical documentation: physician notes, lab results, treatment records.
• Timeline of events: when product was used and when symptoms appeared.
• Recall confirmation: evidence linking product to recalled Dermasarra lots.

Possible Damages You Can Claim

• Reimbursement for medical expenses and treatments.
• Compensation for pain, suffering, and emotional distress.
• Coverage for caregiving costs or lost income if prolonged care required.
• Punitive damages, if evidence shows negligent manufacturing or lack of adequate quality control.

Recall Snapshot

• Recall Date: August 8, 2025
• Product Affected: Dermasarra external analgesic (and associated DermaKleen, KleenFoam products)
• Hazard Identified: Contamination with Burkholderia cepacia complex
• Distribution: Nationwide through pharmacies, medical suppliers, and online
• Consumer Advisory: Discontinue use immediately; dispose properly and contact DermaRite for guidance

Statute of Limitations & Urgency to Act

Product liability actions typically must be initiated within two to three years of injury or discovery. Given the recall occurred in August 2025, it’s vital that any affected individuals seek legal guidance promptly to avoid forfeiture of their claim. Some jurisdictions may offer extended timelines for cases involving latent effects or serious infection.

Frequently Asked Questions

• How do I file a claim? Contact Schmidt & Clark or another experienced product liability attorney to review your materials and initiate the process.
• Are there class action options? Not yet; but if multiple similar cases emerge, consolidation or class certification could become appropriate.
• What evidence should I gather? Medical documentation, purchase or use proof, product packaging, and recall notifications.
• Is emotional distress covered? Yes—cases involving serious or lingering infections could qualify for non-economic damages.
• Should I dispose of the product? Yes—safe disposal was recommended by the recall. Preserve packaging or a photograph if possible for identification purposes.

References

1. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dermarite-industries-issues-voluntary-nationwide-recall-dermakleen-dermasarra-kleenfoam-and